▸ Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.· · ● 1 ▸ Our shares of common stock are thinly traded, and the price may not reflect our value; there can be no assurance that there will be an active market for our shares now or in the future.· · ● 1 ▸ We have a trading symbol for our common stock (“MAIA”) and our common stock is currently listed on the NYSE American.· · ● 1 ▸ Our failure to meet the continued listing requirements of NYSE American could result in a delisting of our common stock.· ● ● 2 ▸ Pandemics, such as COVID-19, may adversely impact our business, results of operations, financial condition, liquidity and cash flows and that of our clients.· ● ● 2 ▸ The limited public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.· ● ● 2 ▸ In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with NYSE American continued listing requirements would be successful.· ● · 1 ▸ An active, liquid trading market for our common stock may not develop.● ● · 2 ▸ Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.● · · 1 ▸ U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand● · · 1 ▸ A variety of risks associated with operating internationally could materially adversely affect our business.● ● ● 3 ▸ Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.● ● ● 3 ▸ Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and prospects.● ● ● 3 ▸ Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.● ● ● 3 ▸ Certain stockholders who are also officers and directors of the Company may have significant control over our management.● ● ● 3 ▸ Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially impact reporting of our financial condition and results of operations.● ● ● 3 ▸ Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.● ● ● 3 ▸ Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.● ● ● 3 ▸ Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes.● ● ● 3 ▸ Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.● ● ● 3 ▸ Development of THIO could take longer, be more expensive, or become impractical if the FDA requires the use of an FDA-approved companion diagnostic test in conjunction with treatment with THIO.● ● ● 3 ▸ Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our development candidates, if approved, and may affect the prices we may set.● ● ● 3 ▸ Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.● ● ● 3 ▸ Even if THIO or any candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.● ● ● 3 ▸ Future sales of our common stock, or the perception in the public markets that these sales may occur, could cause the market price for our common stock to decline.● ● ● 3 ▸ If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.● ● ● 3 ▸ If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing THIO, if approved.● ● ● 3 ▸ If we are unable to obtain FDA approval for our IND application for the planned THIO Phase 2 trial, our clinical development of THIO may be significantly delayed and our business may be substantially harmed.● ● ● 3 ▸ Intellectual property rights do not address all potential threats to our competitive advantage.● ● ● 3 ▸ Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.● ● ● 3 ▸ Our business and operations would suffer in the event of system failures.● ● ● 3 ▸ Our failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, financial condition, and results of operations.● ● ● 3 ▸ Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.● ● ● 3 ▸ Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.● ● ● 3 ▸ Our proprietary information may be lost, or we may suffer security breaches.● ● ● 3 ▸ Our proprietary position for our product candidates currently depends in part upon licenses to patents protecting methods of use, which may not prevent a competitor or other third party from using the same product candidate for another use.● ● ● 3 ▸ Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.● ● ● 3 ▸ Recent legislation may materially adversely affect our financial condition, results of operations and cash flows.● ● ● 3 ▸ Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.● ● ● 3 ▸ group Risks Related to Commercialization● ● ● 3 ▸ Risks Related to Development, Clinical Trials, Manufacturing and Regulatory Approval● ● ● 3 rw ▸ group Risks Related to Healthcare Laws and Other Legal Compliance Matters● ● ● 3 ▸ group Risks Related to Our Dependence on Third Parties● ● ● 3 ▸ group Risks Related to Our Employees, Managing Our Growth and Our Operations● ● ● 3 ▸ Risks Related to Our Financial Position and Need for Additional Capital● ● ● 3 ▸ group Risks Related to Our Intellectual Property● ● ● 3 ▸ group Risks Relating to Our Common Stock● ● ● 3 ▸ The lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially adverse effect on our business.● ● ● 3 ▸ The market opportunities for THIO, if approved, may be smaller than we anticipate.● ● ● 3 ▸ The number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.● ● ● 3 ▸ The price of our common stock may be volatile.● ● ● 3 ▸ The successful commercialization of THIO and any other candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies.● ● ● 3 ▸ Unanticipated changes in the insurance market or factors affecting self-insurance reserve estimates could have a material adverse effect on our business, financial condition and results of operations.● ● ● 3 ▸ We are considered a “smaller reporting company” and are exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.● ● ● 3 ▸ We are considered an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.● ● ● 3 ▸ We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine and Israel and Hamas.● ● ● 3 rw ▸ We are heavily dependent on the success of THIO, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.● ● ● 3 ▸ We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.● ● ● 3 ▸ We could be subject to securities class action litigation.● ● ● 3 ▸ We do not intend to pay dividends for the foreseeable future, and our ability to pay dividends to our stockholders is restricted by applicable laws and regulations.● ● ● 3 ▸ We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.● ● ● 3 ▸ We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.● ● ● 3 ▸ We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.● ● ● 3 ▸ We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.● ● ● 3 ▸ We have never obtained marketing approval for a development candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.● ● ● 3 ▸ We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.● ● ● 3 ▸ We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.● ● ● 3 ▸ We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.● ● ● 3 ▸ We may face early generic competition for THIO or our other products.● ● ● 3 ▸ We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.● ● ● 3 ▸ We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.● ● ● 3 ▸ We may, in the future, issue additional capital stock, which would reduce investors’ percent of ownership and may dilute our share value.● ● ● 3 ▸ We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of THIO.● ● ● 3 
